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Introduction
90-day feeding studies
OECD has developed standard procedures employing 
animal models to assess the toxicity of chemical com-
pounds to humans. In this context, repeated-dose 90-day 
oral (subchronic) toxicity studies are usually carried 
out to evaluate the toxic potential of a chemical in more 
detail after initial information on its toxicity has been 
obtained from acute or repeated-dose 28-day toxicity 
tests. At least three dose levels of a test substance and 
a concurrent control are administered daily per os for a 
period of 90 days to groups of animals (OECD/OCDE 
2014).
This general OECD test approach has been applied to 
the testing of whole food/feed derived from genetically 
modified organisms (GMOs) in order to consider toxic 
effects holistically rather than for a single compound. Tox-
icity studies are now a mandatory part of the risk assess-
ment of genetically modified (GM) food and feed in 
Europe. Although there is a fundamental difference (dos-
ing range) between testing chemicals and whole food/feed, 
repeated-dose 90-day oral toxicity studies nevertheless 
have been included in the integrated approach of assessing 
the potential toxicity of GM plants (EFSA Scientific Com-
mittee 2011). The idea is to administer diets containing the 
plant under study as a component: in treatment groups, this 
component consists of GM plant material (high and low 
doses), and in a control group this component consists of 
conventional plant material. Several observation and exam-
ination data are recorded and compared between the treat-
ment and control groups.
In this paper, we describe the statistical methods 
used for analysing the data from the GRACE 90-day 
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studies (Zeljenková et al. 2014). We compare the traditional 
ANOVA approach with a more modern LMM approach, 
and we investigate the use of standardized effect sizes as 
proposed by EFSA (2011).
Statistical significance and biological relevance
There are several guidelines and publications dealing with 



































Fig. 1  Flowchart representing a statistical decision tree for analys-
ing data in 90-day toxicology studies. a Kolmogorov–Smirnov (with 
Lilliefors correction) test and Shapiro–Wilk test, Q–Q plots, b loga-
rithmic, logit or square root transformation, c Levene test, d Kruskal–
Wallis test, e Dunnett’s test or Turkey test, f Wilcoxon test
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2011; EFSA Scientific Committee 2011; Festing and Alt-
man 2002; OECD Environment, Health and Safety Pub-
lications 2012). OECD in its guidance document No. 116 
mentions that there is no single approach to the statistical 
analysis of data and that statistical methods continue to 
develop so that new and modified approaches may continue 
to be proposed (OECD Environment, Health and Safety 
Publications 2012). Most of the guidelines favour a tradi-
tional approach (i.e. hypothesis testing, P value), which 
simply asks ‘Is there an effect?’, while other more recently 
published papers promote the reporting of effect sizes and 
confidence intervals and to ask ‘How much of an effect is 
there?’ (Ellis 2010; Nuzzo 2014).
Most importantly, biological relevance should always be 
preferred over statistical significance in any evidence-based 
decision-making. Statistical analysis is a (undoubtedly very 
useful) tool for extracting information from data and help-
ing scientists blend data and background knowledge to 
derive scientific conclusions—no more and no less. Denot-
ing something as statistically significant does not mean it is 
biologically relevant. Statistical significance is determined 
by the precision of the measurements, and as such is not 
connected to the biological relevance of observed differ-
ences. Therefore, another element has to enter the discus-
sion if biological relevance is of prime importance, as it is 
for decision-making in risk management. This element is 
the setting of limits for relevance, called ‘equivalence lim-
its’ (European Commission 2013) or alternatively ‘limits of 
concern’ (EFSA Panel on Genetically Modified Organisms 
2010). Statistical measures like ‘significant’ test results and 
P values always need interpretation, when one considers 
what they really mean: the chance of observing data under 
the assumption of a null hypothesis (of no correlation or 
no effect); therefore, they only reflect the likelihood that 
the null hypothesis is true. When the UK statistician Ron-
ald Fisher introduced the P value in the 1920s, he did not 
mean it to be a definite decision basis. However, this was 
the beginning of a movement towards rigorous and objec-
tive decision-making based on P values, statistical power, 
false positives and false negatives—and disregarding the 
biological interpretation by simply classifying results as 
significant or not significant (Nuzzo 2014).
The discussion on the different number of significant 
differences reported by Lemen et al. (2002) and Séralini 
et al. (2007) when analysing the same MON863 90-day 
feeding study very nicely demonstrates this dilemma. 
EFSA (2007) summarized that both studies reported sig-
nificant differences for the same 25 endpoints. Moreover, 
Lemen et al. (2002) described a further 10 significant dif-
ferences not reported by Séralini et al. (2007), while Séra-
lini et al. (2007) pointed out a further 13 significant differ-
ences not reported by Lemen et al. (2002). Furthermore, 
Séralini et al. (2007) found significant differences in 40 out 
of 494 tests and claimed that only 25 would be expected 
by chance alone. Such counting only causes confusion and 
uncertainty. As EFSA emphasizes in its study, statistically 
significant differences must be evaluated with respect to 
their biological relevance. This is equally true for non-sig-
nificant differences as it would be unacceptable if biologi-
cally relevant effects went unnoticed for the lack of statis-
tical power. For this reason, a prospective power analysis 
has been made mandatory in GMO risk assessment (EFSA 
Scientific Committee 2011). In summary, the relevance of 
statistical significance is limited.
Traditional P value approach versus LMM and SES
When performing 90-day toxicity feeding studies, two 
types of endpoints are usually analysed: weight and feed 
consumption are recorded weekly (‘weight and feed con-
sumption data’). Organ weights, haematology and clinical 
biochemistry, as well as gross necropsy and histopathology 
parameters, are surveyed once at the end of the study (‘other 
endpoints’). All these endpoints are compared between the 
groups and tested with relevant baseline values to identify 
any test substance- and dose-dependent toxic responses.
The traditional approach (i.e. hypothesis testing, P value) 
focuses on the analysis of variance (ANOVA) followed by 
post hoc tests. ANOVA compares group (treatments, control) 
means separately for each factor level (e.g. gender: male/
female) and separately for each endpoint (i.e. weight data are 





Fig. 2  Simplified version of a graph allowing visual assessment of 
statistical significance and biological relevance of group compari-
sons. The SES point estimate (circle) and the 95 % confidence limits 
(whiskers, bars showing confidence interval) illustrate the (standard-
ized) effect size between two groups. The vertical black line indicates 
no effect (zero difference), and vertical grey lines indicate biologi-
cal relevance limits (here 1.0 SD, according to the study design). If 
the confidence interval bars cross the zero line but not the grey lines, 
therefore lie within the ±1.0 limits, there is evidence for no statistical 
significance as well as no biological relevance (case a). Two groups 
are significantly different when the confidence interval bars do not 
cross the black vertical line (cases b, c). The effect size between two 
groups is supposed to be biologically (toxically) relevant, when the 
confidence interval bars lie outside the ±1.0 limits (case c). Case b 
indicates statistical significance, but no clear biological relevance. 
Case d indicates no statistical significance, but no clear negation of 
biological relevance [reproduced from Zeljenková et al. (2014)]
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also independently analysed week-by-week). The choice of 
statistical method depends on whether the data are qualita-
tive or quantitative and whether the generic assumptions 
underlying the specific test are met (OECD Environment, 
Health and Safety Publications 2012). Figure 1 presents a 
typical decision tree for the choice of statistical tests when 
analysing toxicity studies. Following the logic of this deci-
sion tree, ANOVA is applied for quantitative data, independ-
ent observations with normally distributed residuals and with 
equal variances in the groups, whereas nonparametric tests 
are applied for qualitative data and when the assumption of 
normality and/or variance homogeneity are not met (accord-
ing to the normality and variance homogeneity tests indi-
cated in Fig. 1). Nonparametric tests are usually limited to 
these cases, since they have lower power compared to their 
parametric counterparts when the corresponding assump-
tions are met. Most of the endpoints in 90-day toxicity 
studies are quantitative: body and organ weights, haematol-
ogy and clinical biochemistry data are continuous data, and 
numbers of blood cells are discrete counts. Nevertheless, the 
assumptions of normal distribution and variance homogene-
ity are often not met. In this case, data may be transformed 
Table 1  Test results (ANOVA, Levene’s test and post hoc Dunnett’s test) for mean male body weights (g) in feeding trial B
Endpoint Equality of group 
means (ANOVA)
Homogeneity of  
variances: (Levene’s test)
Equality of group means post hoc tests (Dunnett)








Body weight in week 0 0.48 0.75 2.98 0.03 0.97 0.64 0.97 0.99
Body weight in week 1 1.18 0.34 0.61 0.66 0.85 0.60 1.00 0.83
Body weight in week 2 1.69 0.17 0.42 0.79 0.80 0.46 0.99 0.67
Body weight in week 3 1.13 0.36 0.85 0.50 0.79 0.67 0.99 0.83
Body weight in week 4 1.16 0.35 1.99 0.12 0.78 0.43 0.96 0.96
Body weight in week 5 0.74 0.57 1.48 0.23 0.75 0.85 0.92 0.96
Body weight in week 6 0.46 0.76 1.37 0.26 0.81 0.96 0.95 0.99
Body weight in week 7 0.32 0.86 1.43 0.24 0.94 0.99 0.97 0.98
Body weight in week 8 0.49 0.75 1.52 0.22 0.78 0.99 0.98 0.98
Body weight in week 9 0.33 0.85 1.56 0.21 0.92 1.00 0.98 0.98
Body weight in week 10 0.55 0.70 1.74 0.16 0.69 0.99 0.97 0.99
Body weight in week 11 0.36 0.84 1.97 0.12 0.94 0.99 0.99 0.99
Body weight in week 12 0.32 0.86 2.02 0.11 0.95 0.98 0.98 0.99
Body weight in week 13 0.29 0.88 1.85 0.14 0.85 0.99 0.97 0.99
Table 2  Body weights (g) in feeding trial B, male rats (mean ± standard deviation)
a Week 13 = 5 days
Endpoint Control 11 % GMO 33 % GMO Conventional 1 Conventional 2
Body weight in week 0 145.70 ± 3.73 144.79 ± 1.56 143.50 ± 3.33 144.74 ± 4.14 145.97 ± 5.91
Body weight in week 1 197.31 ± 6.12 194.34 ± 8.30 192.91 ± 6.21 197.20 ± 7.04 200.44 ± 9.70
Body weight in week 2 241.62 ± 7.53 237.47 ± 9.74 235.03 ± 9.96 240.48 ± 8.92 246.72 ± 11.63
Body weight in week 3 278.37 ± 9.03 272.96 ± 13.61 271.81 ± 13.05 276.24 ± 10.22 283.42 ± 14.72
Body weight in week 4 305.13 ± 11.40 297.84 ± 16.99 293.66 ± 22.24 301.07 ± 10.33 309.36 ± 16.65
Body weight in week 5 329.59 ± 13.41 321.48 ± 18.32 322.85 ± 23.12 324.18 ± 11.21 334.07 ± 17.91
Body weight in week 6 349.99 ± 14.27 342.25 ± 21.04 345.26 ± 24.52 344.97 ± 11.29 353.04 ± 15.83
Body weight in week 7 364.05 ± 17.00 357.76 ± 25.68 362.42 ± 29.30 358.95 ± 11.56 368.45 ± 18.69
Body weight in week 8 377.98 ± 17.71 368.14 ± 21.79 376.49 ± 32.15 373.63 ± 12.59 382.67 ± 19.91
Body weight in week 9 392.65 ± 19.90 384.88 ± 29.18 393.42 ± 34.91 387.59 ± 11.16 397.77 ± 22.36
Body weight in week 10 399.65 ± 19.92 386.42 ± 34.54 401.16 ± 34.09 393.36 ± 11.97 402.69 ± 19.34
Body weight in week 11 404.31 ± 20.26 396.99 ± 31.38 409.03 ± 35.24 399.66 ± 12.14 408.15 ± 17.34
Body weight in week 12 415.46 ± 22.17 408.07 ± 34.21 421.24 ± 39.45 409.53 ± 11.07 416.83 ± 18.81
Body weight in week 13a 419.84 ± 22.86 409.19 ± 32.42 422.44 ± 39.81 413.54 ± 11.59 417.34 ± 21.28
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(logarithmic, logit, square root transformation) to improve 
the normality or variance homogeneity. ANOVA is initially 
applied to test the overall hypothesis that there are no dif-
ferences among the group means. In the event that ANOVA 
delivers a significant result, certain differences between two 
groups are examined case-by-case applying either post hoc 
tests or orthogonal contrasts. The most frequently used post 
hoc tests are Dunnett’s test to compare each treatment group 
with the control and Tukey’s test to compare groups pair-
wise. Gross necropsy and histopathology data are qualitative 
data (categorical, binary or ordinal). For qualitative data and 
quantitative data in which the ANOVA assumptions are not 
met, the Kruskal–Wallis test is applied as an overall test of 
significant differences, and the Wilcoxon test is applied to 
individually compare two groups. Note that these nonpara-
metric tests assume equal variances as well, and in case of 
heteroscedasticity, the Kruskal–Wallis test is not better than 
an ANOVA. Nevertheless, in view of the lack of any alterna-
tive for a nonparametric test, the Kruskal–Wallis is named by 
the OECD Guidance Document 116 (OECD Environment, 
Health and Safety Publications 2012).
Since ANOVA tolerates deviations from the assumptions 
and parametric tests are usually more powerful and versatile, 
it is sometimes applied to all variables. A more conservative 
approach is to apply only nonparametric tests to all variables.
Finally, all results are presented in tables (group means 
and standard deviations per factor level) and bar or line 
graphs with asterisks marking significant differences.
Linear mixed models (LMMs) allow weight develop-
ment in growth curves to be analysed as repeated meas-
urements over time. They are robust with respect to the 
assumptions of normal distribution, homogeneity of vari-
ance and error independence. Moreover, they allow a 
comprehensive analysis of weight data of a study, thereby 
incorporating all model factors with interactions such as 
group, dose and gender plus the development over time. 
When compared to the week-by-week ANOVA with mul-
tiple test results (for all group comparisons) per week, 
this approach results in only one statement on differences 
in weight development between groups. Taking time as a 
fixed factor to indicate repeated measurements allows mod-
elling of time and interactions as well as taking account of 
serial correlations and reducing residual variance.
An effect size in a toxicology study endpoint is the dif-
ference (e.g. treatment vs. control) of means per group. 
Whether the size of an effect is biologically relevant has to 
be assessed by comparing it to an equivalence limit or limit 
of concern set by a toxicologist or other expert. A standard-
ized effect size (SES) is the difference between two group 
means divided by a standardizing factor, for which EFSA 
(2011) has proposed the pooled standard deviation (SD). 
With this standardization, all endpoints are transformed and 
expressed in SD units, allowing comparison of different end-
points (organ weights, haematology and clinical biochem-
istry parameters) of the same study (Festing 2014). There-
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Fig. 3  Line plot of mean male body weights (g) in feeding trial B
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glance. Furthermore, SES enables statistical significance and 
biological relevance (in SD units) to be illustrated simultane-
ously when the equivalence limits are also indicated in the 
display. EFSA (2011) gives the example where differences 
of one unit of SD are considered of little toxicological rel-
evance. The equivalence limits can then be set at 1 for the 
SES, and in this work, we will follow this example.
Materials and methods
We used data from two 90-day feeding trials with two dif-
ferent GM maize MON810 varieties performed within the 
GRACE project (GMO Risk Assessment and Communication 
of Evidence; www.grace-fp7.eu) funded by the European 
Commission within the Seventh Framework Programme 
(Zeljenková et al. 2014). Both feeding trials incorporated five 
groups: two treatment groups (33 % GM maize [33 % GMO], 
11 % GM maize [11 % GMO]), a control group (33 % con-
trol maize [control]) and two additional groups (conventional 
maize varieties [conventional 1] and [conventional 2]). The 
total number of animals per feeding trial was 160 with 16 ani-
mals (8 cages) per gender and dietary treatment.
Each animal was weighed on the first day of the feed-
ing trial, once weekly during the feeding trial and at the 
end of the feeding trial. Feed consumption was deter-
mined once weekly and reported as the total amount of 
feed consumed by two animals in one cage per week. 
Table 3  LMM results for weight in feeding trial B, male rats
(a) Type 3 tests of fixed effects
Effect Num DF Den DF F value P value
 Intercept 1 29.5 27.56 <0.0001
 Group 4 29.5 0.95 0.4473
 Day 1 16.4 1851.35 <0.0001
 Day*group 4 16.4 1.06 0.4059
(b) Least squares means (α = 0.05)
Group Estimate Standard error DF t value Lower CI Upper CI
 Control 271.82 6.6855 31.3 40.66 258.19 285.45
 11 % GMO 265.95 6.6855 31.3 39.78 252.32 279.58
 33 % GMO 272.60 6.6855 31.3 40.78 258.98 286.23
 Conventional 1 268.73 6.6855 31.3 40.20 255.10 282.36
 Conventional 2 270.06 6.6855 31.3 40.40 256.43 283.69
(c) Differences of least squares means (α = 0.05)
Group Group Estimate Standard error DF t value P value Lower CI Upper CI
 11 % GMO 33 % GMO −6.6580 9.4547 31.3 −0.70 0.4865 −25.9324 12.6165
 11 % GMO Control −5.8732 9.4547 31.3 −0.62 0.5390 −25.1476 13.4012
 11 % GMO Conventional 1 −2.7831 9.4547 31.3 −0.29 0.7704 −22.0575 16.4913
 11 % GMO Conventional 2 −4.1152 9.4547 31.3 −0.44 0.6664 −23.3896 15.1592
 33 % GMO Control 0.7848 9.4547 31.3 0.08 0.9344 −18.4896 20.0592
 33 % GMO Conventional 1 3.8748 9.4547 31.3 0.41 0.6847 −15.3996 23.1493
 33 % GMO Conventional 2 2.5428 9.4547 31.3 0.27 0.7897 −16.7316 21.8172
 Control Conventional 1 3.0901 9.4547 31.3 0.33 0.7460 −16.1843 22.3645
 Control Conventional 2 1.7580 9.4547 31.3 0.19 0.8537 −17.5164 21.0324
 Conventional 1 Conventional 2 −1.3320 9.4547 31.3 −0.14 0.8889 −20.6065 17.9424
(d) SES with confidence intervals for mean weight in feeding trial B, male rats
Groups SES Lower CI Upper CI
 Control—11 % GMO 0.1550 −0.8993 1.2093
 Control—33 % GMO −0.0200 −1.0727 1.0327
 Control—conventional 1 0.0825 −0.9706 1.1356
 Control—conventional 2 0.0475 −1.0053 1.1003
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White blood cell count (WBC), red blood cell count 
(RBC), haemoglobin concentration (HGB), haematocrit 
(HCT), mean cell volume (MCV), mean corpuscular hae-
moglobin (MCH), mean corpuscular haemoglobin con-
centration (MCHC), platelet count (PLT), lymphocyte 
count (LYM) and differential leucocyte count param-
eters were measured for the haematology analyses. For 
the clinical biochemistry analyses, the parameters alka-
line phosphatase (ALP), alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), albumin (ALB), total 
protein (TP), glucose (GLU), creatinine (CREA), urea 
(U), cholesterol (CHOL), triglycerides (TRG), calcium 
(Ca), chloride (Cl), potassium (K), sodium (Na) and 
phosphorus (P) were measured. Moreover, the wet weight 
of the kidneys, spleen, liver, adrenal glands, pancreas, 
lung, heart, thymus, testes, epididymides, uterus, ovaries 
and brain of all animals was recorded (The collated pri-
mary data are available through the website http://www.
cadima.info.).
Two animals were housed per cage. Consequently, the 
cage was considered the experimental unit and means per 
cage were calculated for all measurements prior to the sta-
tistical analysis.
Data check and quality control
Raw data from both trials were screened for their struc-
ture and data, and variable definitions were determined. 
Based on these definitions, an SAS analysis data set was 
created. Mean values per cage (experimental unit) were 
calculated for all endpoints except feed consumption. Sec-
ondary variables like weight gain per week or organ/body 
weights were re-computed. All variables were format-
ted and labelled. The SAS data set was locked to exclude 
further modifications. An SPSS data file and an Excel file 
were exported from this SAS data set.
Data were screened for outliers and extreme values. Box 
and whisker plots were created for each gender-group fac-
tor level combination and all variables to identify extreme 
values (variable values within the 1.5* and 3* interquar-
tile range and variable values outside the 3* interquartile 
range). Extreme values were recorded in an Excel sheet for 
easier identification of irregular patterns or abnormal ani-
mals. Growth curves for all animals were plotted (scatter 
plots, weight against study day) and visually inspected for 
irregular patterns.
To describe the data, summary statistics including 
means, standard deviations, 95 % confidence intervals, 
medians, number of valid values, minima and maxima were 
calculated and tabulated. In addition to the box and whisker 
plots, plots of means and 95 % confidence intervals were 
drawn. Descriptive analysis was performed separately for 
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Table 6  Relative organ weights, haematology and clinical biochemistry parameters (cage mean ± SD) of male rats in the feeding trial B
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin, TP total protein, GLU glucose, CREA 
creatinine, U urea, CHOL cholesterol, TRG triglycerides, Ca calcium, Cl chloride, K potassium, Na sodium, P phosphorus. Except where indi-
cated (a n = 15), the number of rats analysed was 16
* Statistically significant difference to control group (P < 0.05) based on one-way ANOVA and post hoc Dunnett’s test or Kruskal–Wallis and 
Wilcoxon tests
1 WBC white blood cells, RBC red blood cells, HGB haemoglobin, HCT haematocrit, MCV mean cell volume, MCH mean corpuscular haemo-
globin, MCHC mean corpuscular haemoglobin concentration, PLT platelets, LYM lymphocytes. The number of rats analysed was 16
Endpoint1 Control 11 % GMO 33 % GMO Conventional 1 Conventional 2
1 2 3 4 5 6
Kidney (right) 0.293 ± 0.019 0.292 ± 0.015 0.285 ± 0.019 0.289 ± 0.011 0.298 ± 0.015
Kidney (left) 0.283 ± 0.019 0.293 ± 0.014 0.291 ± 0.020 0.281 ± 0.014 0.294 ± 0.017
Spleen 0.197 ± 0.014 0.196 ± 0.013 0.194 ± 0.020 0.190 ± 0.015 0.187 ± 0.017
Liver 2.305 ± 0.294 2.267 ± 0.088 2.304 ± 0.093 2.230 ± 0.102 2.287 ± 0.215
Adrenal gland (right) 0.006 ± 0.001 0.006 ± 0.001 0.006 ± 0.001 0.005 ± 0.001 0.006 ± 0.001
Adrenal gland (left) 0.007 ± 0.002 0.007 ± 0.002 0.007 ± 0.001 0.007 ± 0.001 0.007 ± 0.001
Lung 0.304 ± 0.016 0.340 ± 0.020* 0.324 ± 0.046 0.315 ± 0.016 0.343 ± 0.030*
Heart 0.225 ± 0.010 0.233 ± 0.013 0.232 ± 0.013 0.225 ± 0.006 0.228 ± 0.012
Thymus 0.120 ± 0.018 0.121 ± 0.023 0.105 ± 0.013 0.105 ± 0.025 0.107 ± 0.010
Pancreas 0.141 ± 0.026 0.129 ± 0.011 0.126 ± 0.013 0.137 ± 0.016 0.127 ± 0.013
Testis (right) 0.472 ± 0.039 0.501 ± 0.057 0.468 ± 0.032 0.484 ± 0.046 0.473 ± 0.022
Testis (left) 0.475 ± 0.038 0.514 ± 0.059 0.471 ± 0.043 0.475 ± 0.024 0.473 ± 0.027
Epididymis (right) 0.147 ± 0.012 0.159 ± 0.016 0.160 ± 0.024 0.153 ± 0.009 0.153 ± 0.007
Epididymis (left) 0.151 ± 0.013 0.162 ± 0.018 0.150 ± 0.020 0.153 ± 0.009 0.159 ± 0.007
Brain 0.522 ± 0.027 0.545 ± 0.035 0.526 ± 0.045 0.526 ± 0.015 0.536 ± 0.029
WBC (103/μl) 9.44 ± 1.67 10.57 ± 1.53 12.12 ± 1.95* 10.04 ± 2.60 12.91 ± 2.70*
RBC (106/μl) 8.50 ± 0.23 8.86 ± 0.29* 8.82 ± 0.37 8.46 ± 0.15 8.55 ± 0.30
HGB (g/dl) 16.39 ± 0.32 16.69 ± 0.45 16.61 ± 0.55 16.43 ± 0.49 16.48 ± 0.41
HCT (%) 47.21 ± 1.09 49.04 ± 1.41* 48.76 ± 2.00 47.06 ± 1.21 47.55 ± 1.22
MCV (fl) 55.60 ± 0.73 55.38 ± 1.22 55.27 ± 0.82 55.61 ± 0.78 55.66 ± 1.02
MCH (pg) 19.31 ± 0.39 18.85 ± 0.63 18.84 ± 0.59 19.43 ± 0.46 19.30 ± 0.35
MCHC (g/dl) 34.73 ± 0.38 34.04 ± 0.53* 34.08 ± 0.66* 34.91 ± 0.43 34.64 ± 0.17
PLT (103/μl) 838.13 ± 60.16 844.06 ± 68.74 862.19 ± 74.94 874.44 ± 51.34 921.13 ± 52.71*
LYM (103/μl) 8.17 ± 1.38 8.69 ± 1.32 9.88 ± 1.50* 8.35 ± 1.95 10.50 ± 1.23 *
Lymphocytes (%) 78.66 ± 2.44 79.25 ± 3.75 80.72 ± 2.26 79.44 ± 3.50 80.06 ± 3.60
Neutrophils (%) 14.91 ± 1.81 15.63 ± 3.79 14.47 ± 1.88 15.00 ± 3.32 14.97 ± 2.43
Monocytes (%) 4.81 ± 0.98 3.13 ± 0.64* 3.50 ± 1.13* 3.81 ± 0.73* 3.06 ± 0.78*
Eosinophils (%) 1.59 ± 0.72 1.97 ± 0.99 1.31 ± 0.65 1.75 ± 1.15 1.91 ± 0.76
ALP (μkat/l) 1.34 ± 0.20 1.39 ± 0.13a 1.50 ± 0.17 1.37 ± 0.20 1.24 ± 0.08
ALT (μkat/l) 0.61 ± 0.05 0.60 ± 0.07a 0.61 ± 0.04 0.64 ± 0.04 0.69 ± 0.20
AST(μkat/l) 0.96 ± 0.16 1.00 ± 0.08a 1.02 ± 0.14 0.97 ± 0.14 0.94 ± 0.13
ALB (g/l) 33.61 ± 1.07 33.85 ± 1.72a 33.27 ± 1.70 33.63 ± 0.73 32.43 ± 2.37
GLU (mmol/l) 9.41 ± 1.72 9.21 ± 1.32a 9.22 ± 1.95 10.52 ± 1.95 10.28 ± 1.58
CREA (μmol/l) 41.19 ± 6.92 41.68 ± 3.10a 41.28 ± 3.10 47.68 ± 6.46* 44.40 ± 4.82
TP (g/l) 59.59 ± 1.34 59.83 ± 3.66a 58.93 ± 4.28 59.20 ± 2.25 59.27 ± 2.49
U (mmol/l) 5.62 ± 0.42 6.20 ± 0.47a* 6.45 ± 0.67* 6.43 ± 0.78* 6.63 ± 1.18*
CHOL (mmol/l) 2.30 ± 0.24 2.26 ± 0.24a 2.45 ± 0.32 2.47 ± 0.24 2.17 ± 0.18
TRG (mmol/l) 0.65 ± 0.37a 0.84 ± 0.40a 0.78 ± 0.22 0.54 ± 0.16 0.80 ± 0.14
Ca (mmol/l) 2.40 ± 0.22a 2.75 ± 0.23a* 2.73 ± 0.07* 2.42 ± 0.17 2.56 ± 0.18
Cl (mmol/l) 109.81 ± 1.67 107.25 ± 6.24a 108.00 ± 3.75 107.75 ± 2.75 106.16 ± 2.89*
K (mmol/l) 4.47 ± 0.14a 4.50 ± 0.43a 4.66 ± 0.24 4.58 ± 0.43 4.76 ± 0.53
Na (mmol/l) 149.94 ± 0.78a 144.53 ± 5.40a* 146.77 ± 3.07* 149.00 ± 2.30 147.50 ± 4.15
P (mmol/l) 2.51 ± 0.16a 2.84 ± 0.19a* 2.64 ± 0.22 2.48 ± 0.12 2.99 ± 0.95
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To check the normality of the data, Kolmogorov–
Smirnov tests (with Lilliefors correction) and Shapiro–
Wilk tests were performed. When significances were iden-
tified, the corresponding normal Q–Q plots were displayed.
Analysis of weight data
Firstly, a traditional analysis with ANOVA was carried 
out for weight and feed consumption data, separately for 
each gender and each week. For four comparisons of par-
ticular interest (control—GMO33 %, control—GMO11 %, 
control—conventional 1, control—conventional 2), post 
hoc Dunnett’s tests were performed. There were no miss-
ing data, and the data set was fully balanced in each week; 
therefore, the default type III sum of square procedure was 
used for the ANOVA. Levene’s test to check homogene-
ity of variance was applied. Test results were presented in 
tables of means and standard deviations, where all means 
of groups GMO11 %, GMO33 %, conventional 1 and 
conventional 2 differing significantly from control group 
means were marked with asterisks.
Secondly, weight and feed consumption data were ana-
lysed with mixed models, using the restricted maximum 
likelihood (REML) algorithm with Toeplitz covariance 
structure. Group (five levels) was considered a fixed factor. 
The factor week (time in weeks from the start of the experi-
ment) or day (time in days from the start of the experiment) 
was considered a continuous fixed factor. For the result-
ing least square means, standardized effect sizes as well as 
their 95 % confidence intervals were calculated according 
to Nakagawa and Cuthill (2007).
Analysis of all other endpoints
Firstly, a traditional frequentist analysis with ANOVA and 
N-sample nonparametric tests was carried out for all other 
endpoints separately for each gender, and post hoc Dun-
nett’s tests and two-sample nonparametric Wilcoxon tests 
were performed for four comparisons of particular interest 
(control—GMO33 %, control—GMO11 %, control—con-
ventional 1, control—conventional 2).
Secondly, for all other endpoints, standardized effect 
sizes as well as their 95 % confidence intervals were cal-
culated according to (Nakagawa and Cuthill 2007). The 
same four group pairs were compared with each other: 
control—GMO11 %, control—GMO33 %, control—
conventional 1 and control—conventional 2. A bootstrap 
test was applied to compare the variability within paired 
sets of SES (Festing 2014). The idea of this test is to 
investigate whether variation among the SES in the con-
trol versus GM is greater than in the control versus con-
ventional groups (and thus indicating that the GM food 
is toxic).
Graphical presentation of all results
All SES estimates were illustrated graphically, displaying 
both statistical significance and biological relevance for 
each of the endpoint comparison results (Fig. 2). Biological 
relevance here was supposed to be defined by equivalence 
limits of ±1.0 SD, as proposed by EFSA (2011). Body 
weight plus all other endpoints were shown on the same 
graph (separately for male and female), thereby forming an 
overall pattern and allowing the assessment of group com-
parisons at a glance.
For all analyses, we used SAS (SAS Software, ver-
sion 9.4. Copyright, SAS Institute Inc. SAS and all other 
SAS Institute Inc. product or service names are registered 
trademarks or trademarks of SAS Institute Inc., Cary, NC, 
USA). The growth curves were also created with SAS, 
while the SES graphs were created with SPSS (SPSS for 
Windows, version 12.0. Chicago, SPSS Inc.).
Results
In this paper, we show only the results for male rats in feed-
ing trial B of the GRACE study (Zeljenková et al. 2014) 
to compare the traditional and the enhanced approach. The 
full statistical report by Schmidt and Schmidtke (2014) is 
available under www.cadima.info.
Data quality and distribution check
The plotted growth curves did not show any irregular pat-
tern over time. The box plot inspections identified some 
extreme values, mainly in the haematology and clinical 
biochemistry data. Most data were confirmed by the study 
director as not being erroneous. Two biochemistry results 
were excluded due to the fact that the measured values 
were outside the dynamic range of the analyser (animal ID 






SES difference N Mean STD CI95LOW CI95UPP
DIFF_ES_21_31 58 0.04116 0.48269 −1.35008 1.43239
DIFF_ES_21_41 58 0.21315 0.58123 −1.31349 1.73979
DIFF_ES_21_51 58 −0.00969 0.57693 −1.53068 1.51130
DIFF_ES_31_41 58 0.17199 0.52662 −1.28116 1.62515
DIFF_ES_31_51 58 −0.05085 0.50284 −1.47082 1.36912
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Fig. 4  Graphs of standardized effect sizes (a control—GMO11 %, b control—GMO33 %, c control—conventional 1, d control—conventional 
2) of mean body weight plus all other endpoints, male rats, feeding trial B
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45: the potassium value, animal ID 135: the phosphorus 
value). No animals were excluded from the analysis.
Weight development
Levene’s test showed only few significances. The Shapiro–
Wilk normality test as well as the Lillefors modification of 
the Kolmogorov–Smirnov test indicated only single devia-
tions from normality. The results of ANOVA, Levene’s test 
and post hoc Dunnett’s test are shown in Table 1. For male 
rats in trial B, there were no significant differences at all. 
Table 2 shows the means and standard deviations for each 
group and each week. The weekly weight development of 
all groups is displayed in a line graph (Fig. 3).
The results of the LMM analysis are shown in 
Table 3(a). Significant effects of intercept were expected 
from the model choice. Since growth rates differ over time, 
a significant week/day effect was also expected. There is no 
group effect for weight development, and neither is there an 
interaction between group and week/day. Table 3(b) shows 
the least square weight means (i.e. the mean weights over 
time) for the five groups. Table 3(c) shows the differences 
between least square means, indicating that no difference is 
significant.
The SES and confidence intervals for the least square 
means are shown in Table 3(d).
Other endpoints
Results of normality and variance homogeneity testing for 
all other endpoints are presented in Table 4. Significant test 
results, indicating that data are not normally distributed 
or variances are not homogeneous, are italicized. Conse-
quently, column 10 states whether parametric or nonpara-
metric tests should be applied.
The results of ANOVA and N-sample nonparametric 
tests for all other endpoints are shown in Table 5. Signifi-
cant test results are italicized. Column 3 lists the ANOVA 
test results (P values) for the overall test hypothesis that 
there are no differences between the five groups. Column 
9 includes the test results (P values) of the nonparametric 
counterpart (Kruskal–Wallis test). Columns 4–7 show the 
Dunnett’s test results (P values) post hoc to ANOVA for the 
four pairwise group comparisons of interest, while columns 
9–12 show the corresponding nonparametric test results 
(Wilcoxon test post hoc to Kruskal–Wallis).
As is usual, all test results are presented in the form of 
tables with means and standard deviations for each group, and 
significant differences are marked with asterisks (Table 6).
Standardized effects sizes (SES) and confidence inter-
vals are shown in Table 7. Confidence intervals not includ-
ing the zero value, therefore indicating a significant differ-
ence between the groups, are italicized.
Results of ANOVA/Dunnett’s and Kruskal–Wallis/Wil-
coxon test, respectively, can be directly compared with SES 
and their confidence intervals aligning Tables 6 and 7.
It is obvious that the patterns created by highlighting sig-
nificances in italics are the same and that both approaches 
identified the same significances.
The results of the bootstrap test (Table 8) indicate that 
there are no overall differences between the groups for all 
comparisons of interest; i.e. that variation among the SESs 
does not differ between the control versus GM and the con-
trol versus conventional groups.
Graphical presentation of all results
The SES of all endpoints (body weight, organ weights, hae-
matology and clinical biochemistry) with their confidence 
intervals is graphically displayed in Fig. 4. Each graph dis-
plays all information extricable from a group comparison. 
The graphs illustrate the pattern of significances better than 
the asterisk-marked tables. Moreover, not only the ‘yes’ 
(= italicized or marked with asterisks)/‘no’ significances but 
also the sizes of the effects are visualized. Additionally, the 
biological relevance of the effects (defined here by equivalence 
limits of ±1.0 SD—dotted lines) can be directly assessed.
The four graphs in Fig. 4 display the four comparisons 
of interest: control—GMO33 %, control—GMO11 %, 
control—conventional 1, control—conventional 2. Plac-
ing these graphs next to one another allows a direct visual 
comparison of all comparison patterns. This is the most 
effective way to assess the outcome of a feeding study at 
a glance.
Discussion
The availability of software for fitting LMMs has facilitated 
their application in biological sciences. Applying linear 
mixed models to assess developing endpoints like weight 
allows these data to be analysed in a more comprehensive 
and consolidated way and facilitates interpretation. First of 
all, these models enable the complete weight or feed con-
sumption trend to be evaluated and compared, instead of 
individual points in time. They provide a global statement 
on group/treatment differences, which is much easier to 
interpret than a diverse set of single significances between 
different groups at various points in time of the study. Fur-
thermore, by considering time dependency and averaging 
over time points, LMMs are more robust against certain 
deviations from the assumptions on data distribution and 
therefore model such data more precisely.
The traditional approach (OECD Environment, Health 
and Safety Publications 2012) applies one-way ANOVA in 
case of normally distributed variables and equal variation 
750 Arch Toxicol (2016) 90:731–751
1 3
within the treatment groups, and Kruskal–Wallis ANOVA 
if these assumptions are not met. However, in case of het-
eroscedasticity also the Kruskal–Wallis test may give inac-
curate results; therefore, both approaches are incorrect and 
will not help. An alternative approach is to apply Welch’s 
ANOVA test (Kohr and Games 1974), which in turn has 
been criticized to be unable to handle skewed distributions 
(Skovlund 2010). Neuhäuser (2010) proposes to apply the 
generalized Wilcoxon test by Brunner and Munzel (2000). 
Nevertheless, in simulation studies it has been shown that 
non-robustness remains a serious problem with all tests, 
if assumptions of normality and variance homogeneity 
are not met and a final advice is yet to be given (Skovlund 
2010). However—in the absence of an appealing alterna-
tive—for our comparison of the LMM and SES approach 
with the traditional one, we followed the OECD Guidance 
Document 116 and applied the Kruskal–Wallis test, but it 
is obvious that the flexible modelling of the variances is a 
further advantage of the LMM approach.
Reporting and graphically displaying effect sizes and 
confidence intervals can help to avoid the yes/no decision 
trap of statistical tests and to illustrate the size of effects in 
the context of biological relevance. This is supported by 
several publications in the area of toxicology, particularly 
by Festing (2014), who demonstrated the use of SES as a 
data transformation, which can be used in addition to exist-
ing techniques to clarify the results of toxicity tests. OECD 
(2012) states that emphasizing the size of effects and the 
confidence in them avoids the problem of a small, biologi-
cally unimportant effect being declared statistically signif-
icant and the artificiality of trying to dichotomize a result 
into a positive or negative finding on the basis of a P value. 
Furthermore, owing to standardization, all endpoints might 
be displayed in one graph, allowing a pattern of effects to be 
assessed instead of single means and significant differences.
In principle, SES might support the assessment of sta-
tistical significances with respect to their biological rel-
evance. Since they consider the effects, i.e. the differences 
in endpoints between treatments, they allow an assessment 
of the toxicological relevance of the sizes of these effects 
provided that limits for effect sizes of biological/toxicolog-
ical relevance are also expressed on the same scale. For our 
study, we followed EFSA (2011) and applied a rough set-
ting of the equivalence limits of ±1.0 SD by assuming that 
an SES of 1.0 SD or less is unlikely to be of toxicological 
importance.
There are several issues about standardization that are 
open to discussion and could be chosen differently. First, 
the standardization and setting of equivalence limits on a 
dimensionless scale (as multiples of standard deviation) 
might be too abstract for interpretation. Toxicologists might 
prefer to think in the original scales of the various end-
points. Consequently, they might prefer to set equivalence 
limits or limits of concern individually for each endpoint 
and each scale. Second, the pooled standard deviation of 
individual observations SD is determined by both natural 
variation and measurement uncertainty, and is a priori not 
expected to be directly related to biological relevance. If 
external equivalence limits were available, it would be pref-
erable to use these for standardization. Moreover, to assess 
the relevance of the data of a feeding study, toxicologists 
compare correlated parameters (like: liver weight, liver 
necropsy and certain blood values).
The effect size presentation, either supplementing or 
replacing the traditional P value approach, enhances trans-
parency and delivers a more comprehensive overall picture 
of the information derived from the data, which might sup-
port consensus in a decision-making process between all 
actors involved, namely toxicologists, statisticians and reg-
ulators. Furthermore, it helps communicate study results to 
the public in a more easily understood way.
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